, the Company and its subsidiaries earned the net profit pursuant to the Consolidated Financial Statements in the amount of THB 305 million, which is decreased from the same period of the previous year in

Result of Business Operations summarized as follows: 1. The Consolidated Financial Statements 1.1 Report and analysis of Business Operations Revenue Revenue from operations Revenue from operations for the

. Unanimously acknowledged the Company’s performance for the first half year ended August 31, 2018; 2. Unanimously approved the consolidated reviewed 2nd quarter financial statements and six-month period of the

in general greater management participation in SGAH to give more support and necessary controls in the weak areas with the increase in the Company’s direct and indirect equity holding in SGAH from

Seamico Securities Public Company Limited and its subsidiaries (“The Company”) would like to report the consolidated operating result that has been reviewed by our auditor for the first quarter ended March

, 2020 Subject Management’ Discussion and Analysis for the 1st Quarter in 2020 To Directors & Managers The Stock Exchange of Thailand Inter Pharma Public Company Limited (“the Company”) hereby submitting

March 31, 2020 To The President The Stock Exchange of Thailand Management’s Discussion and Analysis Consolidated Financial Statements For three months ended March 31, 2020 Overall Group Performance Table

September 30, 2019 To The President The Stock Exchange of Thailand Management’s Discussion and Analysis Consolidated Financial Statements For nine months ended September 30, 2019 Overall Group Performance

No: AH 02022022 February 28, 2022 Subject: Management Discussion & Analysis (MD&A) for the financial statements of fiscal year 2021 ended as of December 31, 2021 To: The President The Stock Exchange of

No: AH 03112022 November 14th, 2022 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 3rd Quarter of Fiscal Year 2022 Ended as of September 30th, 2022 To: The